Retireful LLC Takes Position in BioNTech SE (NASDAQ:BNTX)

Retireful LLC acquired a new position in BioNTech SE (NASDAQ:BNTX - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm acquired 2,278 shares of the company's stock, valued at approximately $260,000.

Several other hedge funds and other institutional investors have also modified their holdings of BNTX. GAMMA Investing LLC raised its holdings in BioNTech by 21.7% in the third quarter. GAMMA Investing LLC now owns 623 shares of the company's stock valued at $74,000 after buying an additional 111 shares during the period. Blue Trust Inc. raised its stake in shares of BioNTech by 491.1% in the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company's stock valued at $55,000 after acquiring an additional 388 shares during the period. Planning Capital Management Corp lifted its holdings in shares of BioNTech by 45,000.0% during the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company's stock valued at $54,000 after acquiring an additional 450 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in BioNTech by 17.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,931 shares of the company's stock worth $465,000 after purchasing an additional 582 shares during the period. Finally, Slow Capital Inc. boosted its position in BioNTech by 1.2% during the 3rd quarter. Slow Capital Inc. now owns 51,680 shares of the company's stock worth $6,138,000 after purchasing an additional 600 shares during the period. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Stock Down 0.7 %

BioNTech stock traded down $0.83 during midday trading on Friday, hitting $111.93. The stock had a trading volume of 458,339 shares, compared to its average volume of 781,985. The business has a fifty day moving average price of $114.66 and a 200 day moving average price of $104.18. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49. The stock has a market cap of $26.83 billion, a P/E ratio of -53.30 and a beta of 0.18. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating analysts' consensus estimates of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. During the same period in the previous year, the business earned $0.73 EPS. The business's quarterly revenue was up 38.9% on a year-over-year basis. Research analysts predict that BioNTech SE will post -3.71 EPS for the current year.

Analyst Upgrades and Downgrades

BNTX has been the topic of a number of recent research reports. Wells Fargo & Company assumed coverage on BioNTech in a research note on Wednesday, December 11th. They set an "overweight" rating and a $170.00 price objective on the stock. HC Wainwright reissued a "buy" rating and set a $150.00 price target on shares of BioNTech in a research report on Monday, November 18th. BMO Capital Markets restated an "outperform" rating on shares of BioNTech in a report on Monday, December 2nd. Morgan Stanley upgraded shares of BioNTech from an "equal weight" rating to an "overweight" rating and lifted their price objective for the company from $93.00 to $145.00 in a research note on Tuesday, September 24th. Finally, Berenberg Bank initiated coverage on shares of BioNTech in a research note on Tuesday, November 19th. They issued a "buy" rating and a $130.00 target price for the company. Three equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $142.72.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.